Remedy Pharmaceuticals
Remedy Pharmaceuticals is a New York–based, privately held clinical-stage pharmaceutical company focused on developing treatments for acute central nervous system (CNS) injuries and diseases, with an emphasis on therapies for severe ischemic stroke. The company has conducted Phase 2 and Phase 3 clinical trials, holds regulatory interactions with the U.S. FDA, maintains an active patent portfolio, and operates an R&D subsidiary in Australia.
Industries
Nr. of Employees
small (1-50)
Remedy Pharmaceuticals
New York, New York, United States
Patents
Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US-12734182-B2
View DetailsMethods of treating ischemic stroke at risk for cerebral or cerebellar edema
US-12611416-B2
View DetailsMethods of treating ischemic stroke at risk for cerebral or cerebellar edema
US-12337006-B1
View DetailsMethods of treating ischemic stroke at risk for cerebral or cerebellar edema
US-12251389-B1
View DetailsMethods of treating ischemic stroke at risk for cerebral or cerebellar edema
US-12251388-B1
View Details
Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US-12734182-B2
View DetailsMethods of treating ischemic stroke at risk for cerebral or cerebellar edema
US-12611416-B2
View DetailsMethods of treating ischemic stroke at risk for cerebral or cerebellar edema
US-12337006-B1
View DetailsMethods of treating ischemic stroke at risk for cerebral or cerebellar edema
US-12251389-B1
View DetailsMethods of treating ischemic stroke at risk for cerebral or cerebellar edema
US-12251388-B1
View DetailsProducts
Intravenous glyburide formulation (investigational therapeutic for large hemispheric infarction)
A clinical-stage intravenous small-molecule formulation under development to reduce malignant cerebral edema and improve functional outcomes in patients with large-volume ischemic stroke.
CIRARA
CIRARA is an innovative stroke treatment designed to target the SUR1-TRPM4 channel, preventing life-threatening cerebral edema and improving functional outcomes in patients suffering from Large Hemispheric Infarctions (LHI).
Intravenous glyburide formulation (investigational therapeutic for large hemispheric infarction)
A clinical-stage intravenous small-molecule formulation under development to reduce malignant cerebral edema and improve functional outcomes in patients with large-volume ischemic stroke.
CIRARA
CIRARA is an innovative stroke treatment designed to target the SUR1-TRPM4 channel, preventing life-threatening cerebral edema and improving functional outcomes in patients suffering from Large Hemispheric Infarctions (LHI).
Expertise Areas
- Clinical trial management (Phase 2–3)
- Stroke therapeutics development
- Clinical data analysis and biostatistics
- Regulatory strategy and FDA interactions
Key Technologies
- Randomized double-blind placebo-controlled trial design
- CT perfusion (CTP) and MRI diffusion imaging for lesion quantification
- Individual-patient pooled meta-analysis
- Statistical modeling for clinical endpoints (odds ratios, multiple imputation)
News & Updates
USPTO allowed additional patents covering use of the active ingredient and formulation to treat specific LHI patient subgroups, including patients undergoing endovascular therapy and wake-up strokes; allowances provide coverage through mid-2040s with possible extension.
Presentation of pooled analyses and subgroup results from Phase 2 and Phase 3 trials showing statistically significant treatment effects in defined lesion-volume and EVT subgroups.
Company held a Type C meeting with FDA providing feedback on Phase 3 development plans for treatment of large hemispheric infarction.
FDA Office of Orphan Products Division granted Orphan Drug designation for the investigational therapy for large territory acute ischemic stroke.
Analysis showed sustained functional benefit at 12 months in patients with lesion volumes <125 mL and particularly in those treated with endovascular thrombectomy.
Company announced return of the program from a prior sponsor and reported prespecified subgroup and post hoc analyses indicating directionally improved outcomes in multiple subgroups.
USPTO allowed additional patents covering use of the active ingredient and formulation to treat specific LHI patient subgroups, including patients undergoing endovascular therapy and wake-up strokes; allowances provide coverage through mid-2040s with possible extension.
Presentation of pooled analyses and subgroup results from Phase 2 and Phase 3 trials showing statistically significant treatment effects in defined lesion-volume and EVT subgroups.
Company held a Type C meeting with FDA providing feedback on Phase 3 development plans for treatment of large hemispheric infarction.
FDA Office of Orphan Products Division granted Orphan Drug designation for the investigational therapy for large territory acute ischemic stroke.
Analysis showed sustained functional benefit at 12 months in patients with lesion volumes <125 mL and particularly in those treated with endovascular thrombectomy.
Company announced return of the program from a prior sponsor and reported prespecified subgroup and post hoc analyses indicating directionally improved outcomes in multiple subgroups.